Diplomat and OptumRx's combination will expand the innovative specialty pharmacy and infusion solutions that OptumRx can offer.
Diplomat's Q3 revenue was comprised of $1.2 billion from the company’s specialty segment and $82 million from its pharmacy benefit manager segment
Diplomat is retaining a portion of the Envoy Health Management operations that specialize in digital therapeutics and pharmaceutical services.
Cequa is the first and only FDA approved cyclosporine treatment delivered with nanomicellar, or NCELL technology.
Following the retirement of Chris Luthin, David Skomo has been named COO of Diplomat's pharmacy benefit manager CastiaRx.
Betamethasone dipropionate lotion (augmented), 0.05% had a market value of approximately $10 million for the 12 months ended August 2019, according to IQVIA.
AmerisourceBergen has been chosen by Karyopharm to introduce a new treatment for patients with relapsed or refractory multiple myeloma.
Amber Pharmacy will dispense Celgene's Inrebic, a treatment for patients with certain types of myelofibrosis.
PDX is releasing Envoy Dx to meet the needs and custom data feeds required in specialty pharmacy reporting.
AllianceRx Walgreens Prime has added new specialty drugs for patients with rare conditions, such as MS and non-Hodgkin's lymphoma.
Maya Martinez-Davis will assume the role as GSK president of U.S. pharmaceuticals, succeeding Jack Bailey, who will remain as a strategic consultant to GSK through 2020.
Alongside its earnings, Diplomat Pharmacy announced that it is reviewing strategic alternatives, including a sale or merger, as well as pursuing value-enhancing initiatives as a standalone company.
CVS Health's ProCare Pharmacy is adding Premier’s specialty pharmacy business, which serves 367 hospitals across 66 health systems.
Diplomat saw an increase in revenue from its specialty segment in the first quarter but saw revenue and gross profit decrease.